In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

"Prime demonstrated how actual patients saved on prescription drugs as a result of the agreement [between Prime and Express Scripts, Inc. ('ESI')]. With this ruling, AHF is seeking to rewind the clock ...

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...

Hollywood-based AIDS Healthcare Foundation has won a $10.3 million arbitration award in a dispute with a pharmacy benefit ...

Arbitrator issues interim award and Injunction to prevent future wrongdoing by Prime Therapeutics in antitrust case brought by AIDS Healthcare Foundation In a ruling Friday, January 17 ...

Meanwhile, Dr. Manuel López-Figueroa and Dr. Carlos Buesa will remain on the Board, subject to a positive vote by the Shareholders’ Meeting.

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.